AstraZeneca/ZSHP Acquisition Highlights Relypsa (RLYP) is Undervalued - Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail.jpg)
Get Alerts RLYP Hot Sheet
Rating Summary:
3 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 48
Join SI Premium – FREE
Oppenheimer analyst, Ling Wang, believes Relypsa (NASDAQ: RLYP) is undervalued after the acquisition of ZSPH at a value of $2.7B. Competitor ZS-9's interim 52-week data were presented from phase III ZS-005 trial and Wang believes the drugs presented by each company have comparable efficacy. Given the $1.5B valuation gap, the analyst thinks RLYP is undervalued.
The firm reiterated Outperform rating and $55 PT.
For an analyst ratings summary and ratings history on Relypsa, Inc. click here. For more ratings news on Relypsa, Inc. click here.
Shares of Relypsa, Inc. closed at $18.87 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lazard (LAZ) PT Raised to $35 at Goldman Sachs
- argenx SE (ARGX) PT Raised to $861 at Baird
- Meta Platforms Inc. (META) PT Raised to $950 at Mizuho
Create E-mail Alert Related Categories
Analyst Comments, RumorsRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
